Tech Transfer Roundup: How To Protect Downstream Rights
A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.
You may also be interested in...
BlackThorn's series B round will fund the use of AI and machine learning via its PathFinder platform and academic collaborations for the development of targeted therapies.
Private Company Edition: Westlake Village BioPartners launched with $320m and Harper as a managing director; UK-based Ahren unveiled a $100m-plus "deep science" fund; and UCSD partnered with Deerfield to finance drug programs. In new financings, Allogene leads with $120m.
Alkermes tells J.P. Morgan audience it hopes new combo Lybalvi and established Aristada will boost each other and the neuropsychiatric franchise. But the firm noted its addiction drug Vivitrol requires complicated commercial plan.